Macquarie Group
BLCM

Macquarie Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Macquarie Group’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,078
Closed -$35K – 1943
2019
Q2 		$35K Buy
+2,078
New +$56.2K ﹤0.01% 1757

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Macquarie Group's BLCM Position: Q3 2019 in Review

Macquarie Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2019, closing a stake of 2,078 shares — an estimated $35K sold.

Macquarie Group first reported a position in BLCM in Q2 2019 and held it in 1 quarter. The position peaked at $35K in Q2 2019. 67 funds tracked by Wall St. Rank hold BLCM as of Q3 2019.

  • Macquarie Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Macquarie Group sold 2,078 Bellicum Pharmaceuticals, Inc. shares in Q3 2019, an estimated $35K.
  • Macquarie Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Macquarie Group's Bellicum Pharmaceuticals, Inc. position peaked at $35K in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2019.

Based on Macquarie Group's 13F filing for Q3 2019, filed 14 Nov 2019.